O. Reg. 95/23: GENERAL

 

ontario regulation 95/23

made under the

Pharmacy Act, 1991

Made: April 4, 2023
Approved: May 11, 2023
Filed: May 15, 2023
Published on e-Laws: May 15, 2023
Published in The Ontario Gazette: June 3, 2023

Amending O. Reg. 202/94

(General)

1. (1) Paragraph 1 of subsection 34 (3) of Ontario Regulation 202/94 is revoked and the following substituted:

1.  Before performing the act, the member must receive an informed consent from the patient or the patient’s authorized agent.

(2) Subsection 34 (3) of the Regulation is amended by adding the following paragraphs:

7.  Where administering a substance specified in Schedule 1 by injection to a patient through an established central or peripheral venous access device, the member must only do so in collaboration with a member of the College of Nurses of Ontario who is a registered nurse in the extended class or a member of the College of Physicians and Surgeons of Ontario.

8.  Where the act is performed for a purpose other than that of patient education or demonstration the member must, within a reasonable time after performing the act, notify the following persons that the member performed the act, and provide details respecting the act:

i.  The prescriber, if any, of the substance that was administered.

ii.  The patient’s primary care provider, where the member knows that the patient has such a care provider other than the prescriber.

(3) Section 34 of the Regulation is amended by adding the following subsection:

(3.1) Where a limitation or a route of administration is indicated with respect to a substance listed in Schedule 1, a member shall only administer the substance in compliance with the limitation and in accordance with the route of administration specified.

2. Schedules 1 and 2 to the Regulation are revoked and the following substituted:

Schedule 1
Injected Substances

Analgesics and Antipyretics

Codeine — For patient education and demonstration only

Hydromorphone — For patient education and demonstration only

Morphine — For patient education and demonstration only

Nalbuphine — For patient education and demonstration only

Antibacterials

Amikacin

Ampicillin

Cefazolin

Cefepime

Cefotaxime

Cefoxitin

Ceftazidime

Ceftriaxone

Clindamycin

Cloxacillin

Ertapenem

Gentamicin

Penicillin G

Anticholinergic Agents

Scopolamine — Must not be administered intravenously

Hyoscine — Must not be administered intravenously

Glycopyrrolate — Must not be administered intravenously

Anticoagulants

Dalteparin — Must not be administered intravenously

Danaparoid — Must not be administered intravenously

Enoxaparin — Must not be administered intravenously

Fondaparinux — Must not be administered intravenously

Heparin — For patient education and demonstration only

Nadroparin — Must not be administered intravenously

Tinazaparin

Antidiabetic Agents

Exenatide

Insulins

Liraglutide

Dulaglutide

Lixisenatide

Semaglutide

Antihemorrhagic Agents

Emicizumab

Antihistamines

Diphenhydramine — Only for monitoring and management of allergic reactions

Dimenhydrinate — Must not be administered intravenously

Antimigraine Agents

Sumatriptan

Erenumab

Antiparkinsonian Agents

Apomorphine

Benztropine

Antivirals

Enfuvirtide

Interferons

Peginterferon alfa-2a

Central Nervous System Agents, Miscellaneous

Inotersen

Complement Inhibitors

Icatibant

Lanadelumab

Disease-modifying Antirheumatic Drugs

Abatacept

Adalimumab

Anakinra

Etanercept

Golimumab — Must not be administered intravenously

Ustekinumab — Must not be administered intravenously

Methotrexate — Must not be administered intravenously

Sarilumab

Tocilizumab — Must not be administered intravenously

Enzymes

Asfotase Alfa

GI Drugs, Miscellaneous

Certolizumab Pegol

Methylnaltrexone

Gonadotropins and Antigonadotropins

Follitropin-alpha

Follitropin-beta

Follitropin-delta

Gonadotropin-chorionic

Gonadotropin-chorionic-alfa

Lutropin-alfa

Menotropins

Goserelin — For patient education and demonstration only

Triptorelin acetate

Gonadotropin-releasing Hormone Antagonists

Cetrorelix

Ganirelix

Heavy Metal Antagonists

  Deferoxamine — For patient education and demonstration only

Hematopoietic Agents

Darbepoetin alfa — Must not be administered intravenously

Epoetin alfa — Must not be administered intravenously

Filgrastim — Must not be administered intravenously

Pegfilgrastim

Romiplostim — For patient education and demonstration only

Immunomodulatory Agents

Denosumab

Glatiramer

Interferon-Beta-1A

Interferon-Beta-1B

Natalizumab

Immunosuppressive Agents

Belimumab — Must not be administered intravenously

Mepolizumab

Miscellaneous Agents

  Sterile Water for Injection (Diluent)

Sodium Chloride

Parathyroid

Calcitonin Salmon — For patient education and demonstration only

Teriparatide

Pituitary

Desmopressin — For patient education and demonstration only

Vasopressin — For patient education and demonstration only

Progestins

Medroxyprogesterone

Progesterone

Prokinetic Agents

Metoclopramide

Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9) Inhibitors

Alirocumab

Evolocuma

Psychotherapeutic Agents

Haloperidol — For patient education and demonstration only

Methotrimeprazine — For patient education and demonstration only

Respiratory Tract Agents

Omalizumab

Skin And Mucous Membrane Agents

Brodalumab

Dupilumab

Guselkumab

Ixekizumab

Risankizumab — Must not be administered intravenously

Secukinumab

Somatostatin Agonists and Antagonists

Pasireotide

Octreotide — Must not be administered intravenously

Lanreotide

Somatotropin Agonists and Antagonists

Somatropin

Pegvisomant

Tesamorelin

Sympatholytic (Adrenergic Blocking) Agents

Dihydroergotamine — Must not be administered intravenously

Vitamins

Cyanocobalamin

Folic Acid — Must not be administered intravenously

Pyridoxine — Must not be administered intravenously

Thiamine — Must not be administered intravenously

  Ascorbic Acid — Must not be administered intravenously

Vitamin K

Schedule 2
Inhaled Substances

Anticholinergic Agents

Ipratropium

  Tiotropium

Aclidinium

Glycopyrronium

Umeclidinium

Formoterol

Indacaterol

Olodaterol

Salbutamol

Salmeterol

Terbutaline

Vilanterol

Anti-infective Agents

Zanamivir

Levofloxacin

Tobramycin

Aztreonam

Autonomic Drugs, Miscellaneous

  Nicotine

Eye, Ear, Nose and Throat (EENT) Preparations

Sodium Cromoglycate

Beclomethasone

Budesonide

Ciclesonide

Fluticasone

Mometasone

Miscellaneous Agents

Sodium chloride

Sterile water for inhalation

Respiratory Tract Agents

Acetylcysteine

Dornase alfa

Commencement

3. This Regulation comes into force on the later of July 1, 2023 and the day this Regulation is filed.

Made by:

Council of the Ontario College of Pharmacists:

Shenda Tanchak

Registrar and CEO

James Morrison

Board Chair

Date made: April 4, 2023